Monotherapy with Roche's Hivid
Executive Summary
During the week of Aug. 8, FDA is expected to approve monotherapy use of Hivid (ddC) in HIV infection. Although currently approved only for use with AZT in advanced HIV, Hivid is already widely prescribed as monotherapy. In September 1993, FDA's Antiviral Drugs Advisory Committee recommended that ddC be approved as second-line monotherapy for adults with advanced HIV who have shown intolerance to AZT or significant clinical deterioration with AZT
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth